Tick-borne encephalitis virus (TBEV) infection can manifest as disease of variable severity, ranging from subclinical infection to severe disease with neurological involvement and potentially fatal outcome. Although TBE is recognized as a major public health problem in Europe, the true burden of disease is potentially underestimated. Here, we investigated TBEV-specific antibody prevalence, infection incidence, and seroreversion and antibody decline rates in a prospective Swiss healthcare worker (HCW) cohort. We screened serum samples from 1444 HCWs between June and October 2020, and from a subset again between August and September 2021, using a TBEV envelope (E) protein IgG ELISA. Positive samples underwent further analysis with a TBEV non-structural protein 1 (NS1) IgG ELISA, and seroconversions in unvaccinated individuals were confirmed by seroneutralization testing. Questionnaire data were used to determine vaccination status and risk factors. TBEV E protein-specific IgG prevalence was 72.1% (95% CI 68.2-75.7%) in TBEV-vaccinated and 6% (95% CI 4.4-7.8%) in unvaccinated individuals. The estimated annual incidence of infection was 735/100,000. Age was the only factor significantly associated with seroprevalence. The seroreversion rate in unvaccinated individuals was 30.3% within one year, which is almost ten times higher than in vaccinated individuals (3.4%, annual decline rate 8.0%). NS1-specific IgG antibodies were six times more common in vaccinated than unvaccinated HCWs. In conclusion, undetected TBEV infections are common, and infection incidence is much higher than reported clinical cases. Individuals with abortive infections have high antibody decline and seroreversion rates. Whether lifelong protection is conferred and by which immune subsets remain unclear.

Department of Experimental Biology Faculty of Science Masaryk University Brno Czech Republic

Division of Infectious Diseases and Hospital Epidemiology Kantonsspital Baden Baden Switzerland

Division of Infectious Diseases Infection Prevention and Travel Medicine Cantonal Hospital of St Gallen St Gallen Switzerland

Institute of Mathematical Statistics and Actuarial Science University of Bern Bern Switzerland

Interregional Blood Transfusion SRC Bern Switzerland

Laboratory of Arbovirology Institute of Parasitology Biology Centre of the Czech Academy of Sciences Ceske Budejovice Czech Republic

Laboratory of Emerging Viral Infections Veterinary Research Institute Brno Czech Republic

Microbiologie ADMED Analyses et Diagnostics Médicaux La Chaux de Fonds Switzerland

Swiss National Reference Center for Tick Transmitted Diseases Lausanne Switzerland

Thurgau Hospital Group Division of Infectious Diseases and Hospital Epidemiology Muensterlingen Switzerland

Zobrazit více v PubMed

Ruzek, D. et al. Tick-borne encephalitis in Europe and Russia: Review of pathogenesis, clinical features, therapy, and vaccines. Antiviral Res.164, 23–51 (2019). PubMed

Bogovic, P. & Strle, F. Tick-borne encephalitis: A review of epidemiology, clinical characteristics, and management. World J Clin Cases.3(5), 430–441 (2015). PubMed PMC

Ackermann-Gaumann, R. et al. Prevalence of anti-tick-borne encephalitis virus (TBEV) antibodies in Swiss blood donors in 2014–2015. Blood Transfus.21(2), 100–109 (2023). PubMed PMC

BAG. Zahlen zu Infektionskrankheiten Zeckenenzephalitis FSME: Swiss Federal Office of Public Health; [Available from: https://www.bag.admin.ch/bag/de/home/zahlen-und-statistiken/zahlen-zu-infektionskrankheiten.exturl.html/aHR0cHM6Ly9tZWxkZXN5c3RlbWUuYmFnYXBwcy5jaC9pbmZyZX/BvcnRpbmcvZGF0ZW5kZXRhaWxzL2QvZnNtZS5odG1sP3dlYmdy/YWI9aWdub3Jl.html.

Lunácková, J., Chmelík, V., Sípová, I., Zampachová, E. & Becvárová, J. Epidemiologic monitoring of tick-borne encephalitis in Rimov in Southern Bohemia. Epidemiol. Mikrobiol. Imunol.52(2), 51–58 (2003). PubMed

Ackermann-Gaumann, R., Lang, P. & Zens, K. D. Defining the “Correlate(s) of Protection” to tick-borne encephalitis vaccination and infection - key points and outstanding questions. Front. Immunol.15, 1352720 (2024). PubMed PMC

Federal Office for Public Health Switzerland. Cantonal vaccination monitoring. Available online: https://www.bag.admin.ch/bag/de/home/gesund-leben/gesundheitsfoerderung-und-praevention/impfungen-prophylaxe/informationen-fachleute-gesundheitspersonal/durchimpfung.html. Accessed on 06.02.2024. 2022.

Baroutsou, V., Zens, K. D., Sinniger, P., Fehr, J. & Lang, P. Analysis of Tick-borne Encephalitis vaccination coverage and compliance in adults in Switzerland, 2018. Vaccine38(49), 7825–7833 (2020). PubMed

Salat, J. et al. Tick-borne encephalitis virus vaccines contain non-structural protein 1 antigen and may elicit NS1-specific antibody responses in vaccinated individuals. Vaccines8(1), 81 (2020). PubMed PMC

Albinsson, B. et al. Seroprevalence of tick-borne encephalitis virus and vaccination coverage of tick-borne encephalitis, Sweden, 2018 to 2019. Eurosurveillance29(2), 2300221 (2024). PubMed PMC

Euringer, K. et al. Tick-borne encephalitis virus IgG antibody surveillance: vaccination- and infection-induced seroprevalences, south-western Germany, 2021. Eurosurveillance10.2807/1560-7917.ES.2023.28.12.2200408 (2023). PubMed PMC

Ackermann-Gaumann, R. et al. Vaccination against tick-borne encephalitis elicits a detectable NS1 IgG antibody response. J Virol Methods.322, 114831 (2023). PubMed

Kohler, P. et al. Impact of baseline SARS-CoV-2 antibody status on syndromic surveillance and the risk of subsequent COVID-19-a prospective multicenter cohort study. BMC Med.19(1), 270 (2021). PubMed PMC

Zimna, M., Brzuska, G., Salat, J., Ruzek, D. & Krol, E. Influence of adjuvant type and route of administration on the immunogenicity of Leishmania-derived tick-borne encephalitis virus-like particles - A recombinant vaccine candidate. Antiviral Res.228, 105941 (2024). PubMed

Erber W, Schmitt HJ, Jankovic TV. TBE-epidemiology by country—an overview. Chapter 12a. In: Dobler G, Erber W, Bröker M, Schmitt HJ, editors. The TBE Book. Singapore: Global Health Press; 2023.

Bojkiewicz, E. et al. The prevalence of asymptomatic infections with tick-borne encephalitis virus and attitude towards tick-borne encephalitis vaccine in the endemic area of northeastern Poland. Vaccines10(8), 1294. 10.3390/vaccines10081294 (2022). PubMed PMC

Ackermann-Gaumann, R., Tritten, M. L., Hassan, M. & Lienhard, R. Comparison of three commercial IgG and IgM ELISA kits for the detection of tick-borne encephalitis virus antibodies. Ticks Tick Borne Dis.9(4), 956–962 (2018). PubMed

Rendi-Wagner, P. et al. Persistence of protective immunity following vaccination against tick-borne encephalitis–longer than expected?. Vaccine.22(21–22), 2743–2749 (2004). PubMed

Rendi-Wagner, P. et al. Immunogenicity and safety of a booster vaccination against tick-borne encephalitis more than 3 years following the last immunisation. Vaccine23(4), 427–434 (2004). PubMed

Plentz, A., Jilg, W., Schwarz, T. F., Kuhr, H. B. & Zent, O. Long-term persistence of tick-borne encephalitis antibodies in adults 5 years after booster vaccination with Encepur Adults. Vaccine27(6), 853–856 (2009). PubMed

Zent, O. et al. TBE booster immunization according to the rapid immunization schedule: are 3-year booster intervals really necessary?. Vaccine23(3), 312–315 (2004). PubMed

Dorko, E. et al. Effectiveness of primary vaccination against tick-borne encephalitis in employees of the armed forces. Cent Eur J Public Health26(Suppl), S42–S46 (2018). PubMed

Askling, H. H., Vene, S., Rombo, L. & Lindquist, L. Immunogenicity of delayed TBE-vaccine booster. Vaccine30(3), 499–502 (2012). PubMed

Baldovin, T. et al. Persistence of immunity to tick-borne encephalitis after vaccination and natural infection. J. Med. Virol.84(8), 1274–1278 (2012). PubMed

Kriz, B. et al. Results of the screening of tick-borne encephalitis virus antibodies in human sera from eight districts collected two decades apart. Vector Borne Zoonotic Dis.15(8), 489–493 (2015). PubMed

Galgani, I. et al. Systematic literature review comparing rapid 3-dose administration of the GSK tick-borne encephalitis vaccine with other primary immunization schedules. Exp. Rev. Vaccines16(9), 919–932 (2017). PubMed

Loew-Baselli, A. et al. Prevention of tick-borne encephalitis by FSME-IMMUN vaccines: review of a clinical development programme. Vaccine29(43), 7307–7319 (2011). PubMed

Steffen, R., Erber, W. & Schmitt, H. J. Can the booster interval for the tick-borne encephalitis (TBE) vaccine “FSME-IMMUN” be prolonged? - A systematic review. Ticks Tick Borne Dis.12(5), 101779 (2021). PubMed

Zens, K. D. et al. Retrospective, matched case-control analysis of tickborne encephalitis vaccine effectiveness by booster interval, Switzerland 2006–2020. BMJ Open.12(4), e061228 (2022). PubMed PMC

Weiskopf, D., Weinberger, B. & Grubeck-Loebenstein, B. The aging of the immune system. Transpl Int.22(11), 1041–1050 (2009). PubMed

Switzerland FOfPH. Vaccination protects against TBE: reporting data Switzerland, 2002 - 2015. BAG Bulletin. 2016;41:622–6.

Zens KD. TBE in Switzerland and Liechtenstein. Chapter 13. . In: Dobler G, Erber W, Bröcker M, Chitimia-Dobler L, Schmitt HJ, editors. The TBE Book. 7 ed. Singapore: Global Health Press; 2024.

Freimane Z, Dobler G, Chitimia-Dobler L, Karelis G, Girl P, Kuzmane S, et al. Development and validation of a novel enzyme-linked immunosorbent assay for the differentiation of tick-borne encephalitis infections caused by different virus subtypes. Infection. 2024. PubMed PMC

Konishi, E., Kitai, Y. & Kondo, T. Utilization of complement-dependent cytotoxicity to measure low levels of antibodies: application to nonstructural protein 1 in a model of Japanese encephalitis virus. Clin. Vaccine Immunol.15(1), 88–94 (2008). PubMed PMC

Chao, D. Y., Galula, J. U., Shen, W. F., Davis, B. S. & Chang, G. J. Nonstructural protein 1-specific immunoglobulin M and G antibody capture enzyme-linked immunosorbent assays in diagnosis of flaviviral infections in humans. J. Clin. Microbiol.53(2), 557–566 (2015). PubMed PMC